An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Alexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, Gonzalo Tapia, Miguel Garcia, Emmanuelle Medjitna-Rais, Séverine Burnet, Cristina Cellerai, Otto Erlwein, Tristan Barber, Christiane Moog, Peter Liljestrom, Ralf Wagner, Hans Wolf, Jean-Pierre Kraehenbuhl, Mariano Esteban, Jonathan Heeney, Marie-Joelle Frachette, James Tartaglia, Sheena McCormack, Abdel Babiker, Jonathan Weber, Giuseppe Pantaleo, Alexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, Gonzalo Tapia, Miguel Garcia, Emmanuelle Medjitna-Rais, Séverine Burnet, Cristina Cellerai, Otto Erlwein, Tristan Barber, Christiane Moog, Peter Liljestrom, Ralf Wagner, Hans Wolf, Jean-Pierre Kraehenbuhl, Mariano Esteban, Jonathan Heeney, Marie-Joelle Frachette, James Tartaglia, Sheena McCormack, Abdel Babiker, Jonathan Weber, Giuseppe Pantaleo
Abstract
The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C isolate, CN54. 40 volunteers were randomized to receive DNA C or nothing on day 0 and at week 4, followed by NYVAC C at weeks 20 and 24. The primary immunogenicity endpoints were measured at weeks 26 and 28 by the quantification of T cell responses using the interferon gamma enzyme-linked immunospot assay. Our results indicate that the DNA C plus NYVAC C vaccine regimen was highly immunogenic, as indicated by the detection of T cell responses in 90% of vaccinees and was superior to responses induced by NYVAC C alone (33% of responders). The vaccine-induced T cell responses were (a) vigorous in the case of the env response (mean 480 spot-forming units/10(6) mononuclear cells at weeks 26/28), (b) polyfunctional for both CD4 and CD8 T cell responses, (c) broad (the average number of epitopes was 4.2 per responder), and (d) durable (T cell responses were present in 70% of vaccinees at week 72). The vaccine-induced T cell responses were strongest and most frequently directed against Env (91% of vaccines), but smaller responses against Gag-Pol-Nef were also observed in 48% of vaccinees. These results support the development of the poxvirus platform in the HIV vaccine field and the further clinical development of the DNA C plus NYVAC C vaccine regimen.
Figures
References
- Schwartländer, B., J. Stover, N. Walker, L. Bollinger, J.P. Gutierrez, W. McGreevey, M. Opuni, S. Forsythe, L. Kumaranayake, C. Watts, and S. Bertozzi. 2001. AIDS. Resource needs for HIV/AIDS. Science. 292:2434–2436.
- Bart, P.A., A. Harari, and G. Pantaleo. 2006. Clinical studies of experimental vaccines. Current Opinion in HIV & AIDS. 1:286–293.
- Letvin, N.L. 2006. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 6:930–939.
- McMichael, A.J. 2006. HIV vaccines. Annu. Rev. Immunol. 24:227–255.
- Heeney, J.L. 2004. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Rev. Vaccines. 3:S53–S64.
- Desrosiers, R.C. 2004. Prospects for an AIDS vaccine. Nat. Med. 10:221–223.
- Pitisuttithum, P., P.W. Berman, B. Phonrat, P. Suntharasamai, S. Raktham, L.O. Srisuwanvilai, K. Hirunras, D. Kitayaporn, J. Kaewkangwal, S. Migasena, et al. 2004. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J. Acquir. Immune Defic. Syndr. 37:1160–1165.
- Pantaleo, G., and R.A. Koup. 2004. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10:806–810.
- Schmitz, J.E., M.J. Kuroda, S. Santra, V.G. Sasseville, M.A. Simon, M.A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B.J. Scallon, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283:857–860.
- Pantaleo, G., and A. Harari. 2006. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat. Rev. Immunol. 6:417–423.
- Betts, M.R., M.C. Nason, S.M. West, S.C. De Rosa, S.A. Migueles, J. Abraham, M.M. Lederman, J.M. Benito, P.A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 107:4781–4789.
- Koopman, G., D. Mortier, S. Hofman, H. Niphuis, Z. Fagrouch, S. Norley, G. Sutter, P. Liljestrom, and J.L. Heeney. 2004. Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. J. Gen. Virol. 85:2915–2924.
- Johnston, M.I., and A.S. Fauci. 2007. An HIV vaccine–evolving concepts. N. Engl. J. Med. 356:2073–2081.
- Shiver, J.W., and E.A. Emini. 2004. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55:355–372.
- Singh Sandhu, D., and J. Tartaglia. Poxvirus as immunization vehicles. In Vaccines fourth edition. S.A. Plotkins and W.A. Orenstein, editors. 2004. Sauders, Philadelphia. 1297–1316.
- Cebere, I., L. Dorrell, H. McShane, A. Simmons, S. McCormack, C. Schmidt, C. Smith, M. Brooks, J.E. Roberts, S.C. Darwin, et al. 2006. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine. 24:417–425.
- Peters, B.S., W. Jaoko, E. Vardas, G. Panayotakopoulos, P. Fast, C. Schmidt, J. Gilmour, M. Bogoshi, G. Omosa-Manyonyi, L. Dally, et al. 2007. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine. 25:2120–2127.
- Franchini, G., S. Gurunathan, L. Baglyos, S. Plotkin, and J. Tartaglia. 2004. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines. 3:S75–S88.
- Bart, P.A., A. Harari, C. Cellerai, D. Ciuffreda, T. Barber, W. Stoëhr, S. McCormack, G. Pantaleo, J. Weber, and E. Prgm. 2007. EV02, A phase I trial to assess the safety and immunogenicity of DNA C followed by NYVAC C (IM) in an open, randomised comparison to NYVAC C alone in healthy volunteers at low risk of HIV infection. CROI Meeting Paper 101.
- Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745–763.
- Champagne, P., G.S. Ogg, A.S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G.P. Rizzardi, S. Fleury, M. Lipp, et al. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 410:106–111.
- Harari, A., F. Vallelian, and G. Pantaleo. 2004. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur. J. Immunol. 34:3525–3533.
- Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708–712.
- Korber, B.T.M., C. Brander, B.F. Haynes, R. Koup, J.P. Moore, B.D. Walker, and D.I. Watkins, editors. 2005. HIV Molecular Immunology. Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico. pp. 1–1158.
- Kiepiela, P., K. Ngumbela, C. Thobakgale, D. Ramduth, I. Honeyborne, E. Moodley, S. Reddy, C. de Pierres, Z. Mncube, N. Mkhwanazi, et al. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46–53.
- Wilson, N.A., J. Reed, G.S. Napoe, S. Piaskowski, A. Szymanski, J. Furlott, E.J. Gonzalez, L.J. Yant, N.J. Maness, G.E. May, et al. 2006. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80:5875–5885.
- Hel, Z., J. Nacsa, E. Tryniszewska, W.P. Tsai, R.W. Parks, D.C. Montefiori, B.K. Felber, J. Tartaglia, G.N. Pavlakis, and G. Franchini. 2002. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J. Immunol. 169:4778–4787.
- Younes, S.A., B. Yassine-Diab, A.R. Dumont, M.R. Boulassel, Z. Grossman, J.P. Routy, and R.P. Sekaly. 2003. HIV-1 viremia prevents the establishment of interleukin 2–producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198:1909–1922.
- Zimmerli, S.C., A. Harari, C. Cellerai, F. Vallelian, P.A. Bart, and G. Pantaleo. 2005. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA. 102:7239–7244.
- Harari, A., F. Vallelian, P.R. Meylan, and G. Pantaleo. 2005. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J. Immunol. 174:1037–1045.
- Harari, A., S. Petitpierre, F. Vallelian, and G. Pantaleo. 2004. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood. 103:966–972.
- Heeney, J.L., and S.A. Plotkin. 2006. Immunological correlates of protection from HIV infection and disease. Nat. Immunol. 7:1281–1284.
- Harari, A., V. Dutoit, C. Cellerai, P.A. Bart, R.A. Du Pasquier, and G. Pantaleo. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211:236–254.
- Precopio, M.L., M.R. Betts, J. Parrino, D.A. Price, E. Gostick, D.R. Ambrozak, T.E. Asher, D.C. Douek, A. Harari, G. Pantaleo, et al. 2007. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. J. Exp. Med. 204:1405–1416.
- Su, L., M. Graf, Y. Zhang, H. von Briesen, H. Xing, J. Kostler, H. Melzl, H. Wolf, Y. Shao, and R. Wagner. 2000. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B′) recombinant strain in China. J. Virol. 74:11367–11376.
- Cranenburgh, R.M., J.A. Hanak, S.G. Williams, and D.J. Sherratt. 2001. Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res. 29:E26.
- Gomez, C.E., J.L. Najera, V. Jimenez, K. Bieler, J. Wild, L. Kostic, S. Heidari, M. Chen, M.J. Frachette, G. Pantaleo, et al. 2007. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine. 25:1969–1992.
- Currier, J.R., E.G. Kuta, E. Turk, L.B. Earhart, L. Loomis-Price, S. Janetzki, G. Ferrari, D.L. Birx, and J.H. Cox. 2002. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods. 260:157–172.
- Kondo, E., Y. Akatsuka, K. Kuzushima, K. Tsujimura, S. Asakura, K. Tajima, Y. Kagami, Y. Kodera, M. Tanimoto, Y. Morishima, and T. Takahashi. 2004. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood. 103:630–638.
- Burrer, R., D. Salmon-Ceron, S. Richert, G. Pancino, G. Spiridon, S. Haessig, V. Roques, F. Barre-Sinoussi, A.M. Aubertin, and C. Moog. 2001. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients. J. Virol. 75:5421–5424.
- Li, M., F. Gao, J.R. Mascola, L. Stamatatos, V.R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K.M. Greene, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108–10125.
- Holl, V., S. Hemmerter, R. Burrer, S. Schmidt, A. Bohbot, A.M. Aubertin, and C. Moog. 2004. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J. Immunol. 173:6274–6283.
Source: PubMed